Literature DB >> 21748774

Some insight on censored cost estimators.

H Zhao1, Y Cheng, H Bang.   

Abstract

Censored survival data analysis has been studied for many years. Yet, the analysis of censored mark variables, such as medical cost, quality-adjusted lifetime, and repeated events, faces a unique challenge that makes standard survival analysis techniques invalid. Because of the 'informative' censorship imbedded in censored mark variables, the use of the Kaplan-Meier (Journal of the American Statistical Association 1958; 53:457-481) estimator, as an example, will produce biased estimates. Innovative estimators have been developed in the past decade in order to handle this issue. Even though consistent estimators have been proposed, the formulations and interpretations of some estimators are less intuitive to practitioners. On the other hand, more intuitive estimators have been proposed, but their mathematical properties have not been established. In this paper, we prove the analytic identity between some estimators (a statistically motivated estimator and an intuitive estimator) for censored cost data. Efron (1967) made similar investigation for censored survival data (between the Kaplan-Meier estimator and the redistribute-to-the-right algorithm). Therefore, we view our study as an extension of Efron's work to informatively censored data so that our findings could be applied to other marked variables.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21748774      PMCID: PMC3880208          DOI: 10.1002/sim.4295

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  11 in total

1.  On estimating medical cost and incremental cost-effectiveness ratios with censored data.

Authors:  H Zhao; L Tian
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

2.  Linear regression analysis of censored medical costs.

Authors:  D Y Lin
Journal:  Biostatistics       Date:  2000-03       Impact factor: 5.899

3.  On estimators of medical costs with censored data.

Authors:  Anthony O'Hagan; John W Stevens
Journal:  J Health Econ       Date:  2004-05       Impact factor: 3.883

4.  Estimating medical care costs under conditions of censoring.

Authors:  M Raikou; A McGuire
Journal:  J Health Econ       Date:  2004-05       Impact factor: 3.883

5.  Regression methods for cost-effectiveness analysis with censored data.

Authors:  Andrew R Willan; D Y Lin; Andrea Manca
Journal:  Stat Med       Date:  2005-01-15       Impact factor: 2.373

6.  Semi-parametric regression models for cost-effectiveness analysis: improving the efficiency of estimation from censored data.

Authors:  Eleanor M Pullenayegum; Andrew R Willan
Journal:  Stat Med       Date:  2007-07-30       Impact factor: 2.373

7.  On the equivalence of some medical cost estimators with censored data.

Authors:  Hongwei Zhao; Heejung Bang; Hongkun Wang; Phillip E Pfeifer
Journal:  Stat Med       Date:  2007-10-30       Impact factor: 2.373

8.  On estimating costs for economic evaluation in failure time studies.

Authors:  A P Hallstrom; S D Sullivan
Journal:  Med Care       Date:  1998-03       Impact factor: 2.983

9.  Estimating medical costs from incomplete follow-up data.

Authors:  D Y Lin; E J Feuer; R Etzioni; Y Wax
Journal:  Biometrics       Date:  1997-06       Impact factor: 2.571

10.  What price Kaplan-Meier?

Authors:  R G Miller
Journal:  Biometrics       Date:  1983-12       Impact factor: 2.571

View more
  6 in total

1.  Generalized Redistribute-to-the-Right Algorithm: Application to the Analysis of Censored Cost Data.

Authors:  Shuai Chen; Hongwei Zhao
Journal:  J Stat Theory Pract       Date:  2013-04-01

2.  Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

3.  Semiparametric Estimation of Longitudinal Medical Cost Trajectory.

Authors:  Liang Li; Chih-Hsien Wu; Jing Ning; Xuelin Huang; Ya-Chen Tina Shih; Yu Shen
Journal:  J Am Stat Assoc       Date:  2018-06-18       Impact factor: 5.033

4.  Propensity score and doubly robust methods for estimating the effect of treatment on censored cost.

Authors:  Jiaqi Li; Elizabeth Handorf; Justin Bekelman; Nandita Mitra
Journal:  Stat Med       Date:  2015-12-17       Impact factor: 2.373

5.  Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: a French multicentre observational study.

Authors:  Sandrine Baffert; Paul Cottu; Youlia M Kirova; Florence Mercier; Cécile Simondi; Thomas Bachelot; Emilie Le Rhun; Christelle Levy; Maya Gutierrez; Nicolas Madranges; Cristian Moldovan; Bruno Coudert; Dominique Spaëth; Daniel Serin; François-Emery Cotté; Laure Benjamin; Cathie Maillard; Sabine Laulhere-Vigneau; Isabelle Durand-Zaleski
Journal:  BMC Health Serv Res       Date:  2013-10-31       Impact factor: 2.655

6.  The Impact of Hyperkalemia on Mortality and Healthcare Resource Utilization Among Patients With Chronic Kidney Disease: A Matched Cohort Study in China.

Authors:  Jiahui Zhang; Xiaoning He; Jing Wu
Journal:  Front Public Health       Date:  2022-03-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.